Allarity Therapeutics Inc (ALLR) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Allarity Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Allarity Therapeutics Inc 's ROA in the second quarter of 2026?
Allarity Therapeutics Inc recorded a cumulative net loss of $-12 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -46.5%.
However, within the Healthcare sector 541 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3897, from total ROA ranking in the first quarter of 2026 at 4591.
: Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company focused on personalized cancer treatments, recently announced it has successfully regained compliance with the Nasdaq minimum bid price requirement following a significant period of market fluctuations. Concurrently, the company faces legal challenges as Rosen Law Firm reminds investors of important deadlines related to a class action lawsuit. Allarity Therapeutics has been under scrutiny from both market regulators and investors in recent months. The firm s performance on the Nasdaq Stock Market has attracted attention, particularly following its struggle to maintain the minimum bid price requirement that dictates continued listing.
Boston, MA (October 3, 2024) Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company committed to advancing personalized cancer therapies, has recently made significant leadership changes aimed at accelerating the development of its promising PARP inhibitor, Stenoparib. These strategic appointments come at a crucial time as the company seeks to solidify its position in the competitive oncology landscape and drive forward its clinical pipeline.The current leadership reshuffle is poised to enhance Allarity s operational efficiency and strategic decision-making processes, critical components that will support the ongoing development of Stenoparib. The appointments reflect a robust commitment to harnessing the expertise necessary for the advancement of personalized treatment options for cancer patients, particularly in areas with significant unmet medical needs.
Navigating the Complex Terrain of Legal and Financial Challenges in a Biotech Firm As the November 12, 2024 Deadline Approaches, Investors in Allarity Therapeutics, Inc. Consider Legal Recourse New York, Sept. 27, 2024 Rosen Law Firm, a globally recognized leader in investor rights and securities litigation, has issued a reminder to those who purchased securities in Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022, and July 19, 2024 (the Class Period), about the impending lead plaintiff deadline on November 12, 2024. The Legal Context: The law firm encourages investors to secure counsel promptly in light of potential claims that could arise from their investment during the specified timeframe. Class action lawsuits of this nature typically revolve around allegations of misrepresentation or omissions related to the company s operations, financial health, or potential market movements which might affect investors decisions.
Allarity Therapeutics, a clinical-stage pharmaceutical company specializing in the development of personalized oncology therapeutics and companion diagnostics, has announced a significant transition in its leadership. In a recent press release, the company revealed the appointment of Thomas H. Jensen as Interim Chief Executive Officer (CEO) and the engagement of Jeremy R. Graff, PhD, as an Executive Advisor. This strategic move aims to fortify Allarity s research and development programs in the field of small molecule inhibitors for treating cancer, solidifying its position as a frontrunner in the fight against this devastating disease. Background: With a focus on precision medicine, Allarity Therapeutics is at the forefront of developing innovative oncology therapies tailored to individual patients specific needs. Its pioneering approach utilizes drug-specific Drug Response Predictor (DRP) companion diagnostics to identify the most effective treatment options for cancer patients, maximizing therapeutic outcomes while minimizing unnecessary side effects.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
